However, in both tumor models, JHU083 treatment caused a robust TGI despite CD8+ T cell depletion (Fig. 1F and G), suggesting that the antitumor activity of JHU083 is only partially dependent on CD8+ T cells in both tumor models. Here, CD8A is linked to neoplasm.